Drugs capable of simultaneously modulating both AHR and AR signaling pathways could offer a more effective treatment strategy for prostate cancer patients, particularly those with castration-resistant prostate cancer (CRPC), who have limited treatment options [23]. Here, AHR is linked to prostate cancer.